You can buy or sell TrovaGene and other stocks, options, ETFs, and crypto commission-free!
TrovaGene, Inc. Common Stock, also called TrovaGene, is a clinical-stage, precision medicine oncology therapeutics company. Read More Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Guru FocusMar 13
Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
SAN DIEGO, March 13, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that it has received approximately $3.0 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $6.60 per share. The warrants were issued as part of the units sold in the Comp...
Guru FocusMar 12
Trovagene Regains Compliance with Nasdaq Listing Requirements
SAN DIEGO, March 12, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision medicine approach to develop drugs that target cell division (mitosis) for the treatment of leukemias, lymphomas and solid tumor cancers, announced today that it has regained compliance with Nasdaq listing requirements. In a letter dated March 11, 2019, Nasdaq informed the Company that it has regained compliance with the minimum bid price requirement. About Trovagene, ...
What's Behind TrovaGene's Volatile Ride? (NASDAQ:TROV)(NASDAQ:BPTH)
It's déjà vu for biotech investors, who witnessed a wild rally in Bio-Path Holdings Inc (NASDAQ: BPTH) this week. Shares of another thinly traded, nano-cap biotech are clocking double-digit gains for the second consecutive session. TrovaGene Inc (NASDAQ: TROV), which develops therapies targeting cell division to treat leukemia, lymphomas and solid tumors, gained more than 30 percent Thursday and was up about 70 percent midday Friday. The advance came in reaction to the company's fourth-quarter results, re...
-$1.05 per share
-$1.09 per share